Ten patients, with bone marrow failure or malignant disorders, became refractory to platelet transfusions using random, as well as partial or fully HLA-matched, single-donor platelets. To determine its effect on platelet refractoriness, intravenous gamma globulin (IV IgG) was administered at 400 or 800 mg/kg/d for five days, and postinfusion platelet responses were monitored. Platelet transfusion responses following intravenous gamma globulin (IV I96) were graded as follows: Excellent, 48-hour posttransfusion count > 50,000/μL; good, 48-hour count > 20,000 but <50,000/μL; Fair, increased increment, 48-hour count <20,000; and failed, no increased increment. Six of ten patients (60%) had improved responses to selected single-donor platelets (two were excellent, three were good, and one was fair). The time to achieve a platelet transfusion count > 25,000/μL ranged from one to nine days of IgG therapy. One individual had sustained benefit (> 1 year); the remaining responses persisted for 6 to 8 weeks. These results suggest that IV IgG may be useful in the management of platelet refractoriness, especially in patients receiving single-donor platelets.
|Original language||English (US)|
|Number of pages||4|
|State||Published - 1987|
ASJC Scopus subject areas
- Cell Biology